BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder

Journal of Psychiatry and Neuroscience

Volumn 33, Issue 5, 2008, Pages 449-453

  Tseng, Michael ^a   Alda, Martin ^b   Xu, Li ^a   Sun, Xiujun ^f   Wang, Jun Feng ^a   Grof, Paul ^a   Turecki, Gustavo ^c   Rouleau, Guv ^d   Young, L Trevor ^a,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f NONE

Author keywords

Bipolar disorder; Brain derived neurotrophic factor; Enzyme linked immunosorbent assay; Lithium

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; LITHIUM SALT;

ADULT; ARTICLE; B LYMPHOBLAST; BIPOLAR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; LYMPHOCYTE TRANSFORMATION; MALE; MONOTHERAPY; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN FUNCTION; RELATIVE;

EID: 53349119452     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Alda M. The phenotypic spectra of bipolar disorder. Eur Neuropsychopharmacol 2004;14(Suppl 2):S94-9.
2. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4 Suppl):1-50.
3. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005;7(Suppl 3):5-69.
4. Grof P, Alda M, Grof E, et al. Lithium response and genetics of affective disorders. J Affect Disord 1994;32:85-95.
5. Turecki G, Grof P, Cavazzoni P, et al. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry 1998;3:534-8.
6. Alda M, Grof P, Rouleau GA, et al. Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1038-45.
7. Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res. In press.
8. Kanazawa T, Glatt SJ, Kia-Keating B, et al. Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatr Genet 2007;17:165-70.
9. Chen B, Dowlatshahi D, MacQueen G, et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001;50:260-5.
10. Karege F, Schwald M, Papadimitriou P, et al. The cAMP-dependent protein kinase A and brain-derived neurotrophic factor expression in lymphoblast cells of bipolar affective disorder. J Affect Disord 2004;79:187-92.
11. Cunha AB, Frey BN, Andreazza AC, et al. Serum brain-derived neutotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006;398:215-9.
12. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978;35: 837-44.
13. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978;35:773-82.
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: The Association; 1994.
15. Alda M, Keller D, Grof E, et al. Is lithium response related to G(s)alpha levels in transformed lymphoblasts from subjects with bipolar disorder? J Affect Disord 2001;65:117-22.
16. Machado-Vieira R, Dietrich MO, Leke R, et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 2007;61:142-4.
17. Hasler G, Drevets WC, Gould TD, et al. Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 2006; 60:93-105.
18. Einat H, et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003;23:7311-6.
19. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:261-5.
20. Gonul AS, Akdeniz F, Taneli F, et al. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005;255:381-6.
21. Huang T, Lee C, Liu Y. Serum brain-derived neurotropbic factor levels in patients with major depression: effects of antidepressants. J Psychiatr Res 2008;42.521-5.
22. Piccinni A, Marazziti D, Catena M, et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord 2008;105:279-83.
23. Young LT, Woods CM. Mood stabilizers have differential effects on endogenous ADP ribosylation in C6 glioma cells. Eur J Pharmacol 1996;309:215-8.
24. Ozaki N, Chuang DM. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem 1997;69:2336-44.
25. Kato T, Shioiri T, Inubushi T, et al. Brain lithium concentrations measured with lithium-7 magnetic resonance spectroscopy in patients with affective disorders: relationship to erythrocyte and serum concentrations. Biol Psychiatry 1993;33:147-52.
26. Manji HK, Lenox RH. Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 1994;16:11-28.
27. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002;328:261-4.
28. Lang UE, Hellweg R, Seifert F, et al. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol Psychiatry 2007;62:530-5.